Current status and prospects of molecular targeted therapy for liver cancer
10.3760/cma.j.cn121382-20200511-00511
- VernacularTitle:肝癌分子靶向治疗的现状与展望
- Author:
Dazhi TIAN
1
;
Weiqi ZHANG
;
Wentao JIANG
Author Information
1. 天津市第一中心医院肝移植科 300192
- From:
International Journal of Biomedical Engineering
2020;43(5):400-405
- CountryChina
- Language:Chinese
-
Abstract:
Liver cancer is a common liver malignant tumor and a common cause of death related to malignant tumors, which seriously threatens the lives of patients. In recent years, with the in-depth study of the occurrence and development of liver cancer, a clearer understanding of the occurrence and related molecular pathways of liver cancer has been developed, and a variety of molecular targeted drugs have been developed, mainly including anti-angiogenic drugs and immune checkpoints inhibitors. First-line anti-angiogenic drugs include sorafenib and lenvatinib, both of which can effectively prolong the survival of patients with unresectable advanced liver cancer. For patients with intolerable first-line drug adverse reactions or tumor progression during treatment, second-line drugs such as regorafenib and cabozantinib can also be selected, which may help prolong the survival of patients. Immune checkpoint inhibitors mainly include programmed cell death protein 1 and its ligand inhibitors and cytotoxic T lymphocyte-related antigen 4 inhibitors, both of which can inhibit immune checkpoints through a certain mechanism to prevent immune escape of tumor cells, and can effectively prolong the median survival time of patients with unresectable liver cancer. These two inhibitors are gradually being used in the clinical treatment of liver cancer.
